CRT-158 Comparison Of Everolimus- And Paclitaxel-eluting Stents in Dialysis Patients

We previously reported that the incidence of 1-year major adverse cardiac events (MACE) in patients treated with paclitaxel-eluting stents (PES) was lower than that in the sirolimus-eluting stents, mainly due to reduction of target lesion revascularization (TLR) in dialysis patients. However, it is